Definium Therapeutics, Inc.

DFTX

Nasdaq; healthcare; SIC 2833, Medicinal Chemicals & Botanical Products; CIK 0001813814

A

strongest fifth of 370 graded peers in healthcare

rank 63 of 370; percentile 16.8; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	B percentile 31.5
Solvency	B/C percentile 39.9
Growth and financing	B/C percentile 40.3
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $440.1M
Warnings	dilution not computable: degenerate inputs, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 26, 2026 244 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$37.08 2026-10-27; market equity $5.0B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including DT120 (previously referred to as MM120), and DT402 (previously referred to as MM402), our lead product candidates.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 31.5						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(14.1%)	(6.6%)	31.5	805	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 39.9					
Twelve-month failure probability	0.03%	0.07%	22.4	246	2026-06-30
Altman Z double-prime	1.64	(0.33)	30.3	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	(30.34x)	(4.51x)	77.2	80	2025-12-31
Current ratio	6.29x	2.94x	29.7	832	2025-12-31
Growth and financing, sleeve percentile 40.3					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	37.3%	2.1%	12.2	697	2025-12-31
Net share issuance, one year	32.3%	2.5%	68.4	634	2026-02-19

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 32.3%

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
58	Edwards Lifesciences Corp. (EW)	15.4	A	
59	Vertex Pharmaceuticals Inc. MA (VRTX)	15.7	A	
60	RxSight, Inc. (RXST)	16.0	A	fortress balance sheet
61	Ensign Group, Inc. (ENSG)	16.3	A	fortress balance sheet
62	Natures Sunshine Products Inc. (NATR)	16.5	A	fortress balance sheet
63	Definium Therapeutics, Inc. (DFTX)	16.8	A	dilution
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.1	A	
65	Acadia Pharmaceuticals Inc. (ACAD)	17.3	A	
66	Aurinia Pharmaceuticals Inc. (AUPH)	17.6	A/B	
67	UFP Technologies Inc. (UFPT)	17.9	A/B	
68	Conmed Corp. (CNMD)	18.2	A/B	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-27 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	236.9%	7.7%	97
Distance from 52-week high	(23.5%)	(28.6%)	57
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.18	0.28	38
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	1.00	(0.14)	97

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$655.3M
Operating cash flow, four quarters	-$168.0M
Months of runway	46.8
Days since last periodic filing	83 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$75.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$183.8M	2025-12-31	2026-02-26	10-K	26-076742
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$131.6M	2025-12-31	2026-02-26	10-K	26-076742
3	assets	us-gaap:Assets	$440.1M	2025-12-31	2026-02-26	10-K	26-076742
4	assets	us-gaap:Assets	$302.2M	2024-12-31	2026-02-26	10-K	26-076742
5	current assets	us-gaap:AssetsCurrent	$419.3M	2025-12-31	2026-02-26	10-K	26-076742
6	current liabilities	us-gaap:LiabilitiesCurrent	$66.7M	2025-12-31	2026-02-26	10-K	26-076742
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$582.7M	2025-12-31	2026-02-26	10-K	26-076742
8	operating income	us-gaap:OperatingIncomeLoss	-$166.3M	2025-12-31	2026-02-26	10-K	26-076742
9	book equity	us-gaap:StockholdersEquity	$332.3M	2025-12-31	2026-02-26	10-K	26-076742
10	liabilities	us-gaap:Liabilities	$107.8M	2025-12-31	2026-02-26	10-K	26-076742
11	interest expense	us-gaap:InterestExpense	$5.5M	2025-12-31	2026-02-26	10-K	26-076742
12	assets	us-gaap:Assets	$124.5M	2023-12-31	2025-03-06	10-K	25-034176
13	assets	us-gaap:Assets	$170.0M	2022-12-31	2024-02-28	10-K	24-021656
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	99,698,129	2026-02-19	2026-02-26	10-K	26-076742
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	75,368,359	2025-02-20	2025-03-06	10-K	25-034176

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.